Heska: Q4 Earnings Insights
Shares of Heska (NASDAQ:HSKA) were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share were up 928.57% over the past year to $0.72, which beat the estimate of ($0.22).
Revenue of $64,322,000 up by 90.49% year over year, which beat the estimate of $53,090,000.
Looking Ahead
Heska hasn't issued any earnings guidance for the time being.
The upcoming fiscal year's revenue expected to be between $225,000,000 and $235,000,000.
Details Of The Call
Date: Feb 23, 2021
Time: 11:00 AM
ET Webcast URL: http://public.viavid.com/player/index.php?id=143209
Recent Stock Performance
Company's 52-week high was at $206.85
Company's 52-week low was at $50.00
Price action over last quarter: Up 50.55%
Company Profile
Heska Corp is engaged in developing, manufacturing, marketing, selling & supporting veterinary products. The company's segments are Core Companion Animal Health & Other Vaccines, Pharmaceuticals and Products. The CCA segment includes, primarily for canine & feline use, a point of care laboratory instruments & supplies, digital imaging products, software & services, local & cloud-based data services, allergy testing & immunotherapy, & single-use offerings such as point of care diagnostic tests and heartworm preventive products. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other species including equine, porcine, avian, feline & canine.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
